Nyxoah Aktie
WKN DE: A2QCWK / ISIN: BE0974358906
03.06.2024 22:15:00
|
Information on the total number of voting rights and shares
REGULATED INFORMATION
Information on the total number of voting rights and shares
Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
- Share capital: EUR 5,902,793.43
- Total number of securities carrying voting rights: 34,360,390 (all ordinary shares)
- Total number of voting rights (= denominator): 34,360,390 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
-
- 100 "2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);
- 400,500 "2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 400,500 securities carrying voting rights (all ordinary shares); and
- 1,070,500 "2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,070,500 securities carrying voting rights (all ordinary shares); and
- 700,000 "2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).
*
* *
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com
Attachment


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nyxoah S.A. Registered Shsmehr Nachrichten
08.04.25 |
EQS-News: Nyxoah Provides Update on FDA Approvable Letter for Genio System (EQS Group) | |
26.03.25 |
EQS-News: Nyxoah erhält Approvable Letter für sein Genio®-System von der FDA (EQS Group) | |
26.03.25 |
EQS-News: FDA Issues Nyxoah an Approvable Letter for its Genio® System (EQS Group) | |
13.03.25 |
EQS-News: Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results (EQS Group) | |
13.03.25 |
EQS-News: Nyxoah gibt Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 bekannt und informiert über die Unternehmensentwicklung (EQS Group) | |
12.03.25 |
Ausblick: Nyxoah vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
26.02.25 |
Erste Schätzungen: Nyxoah gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
19.02.25 |
EQS-News: Nyxoah gibt die Markteinführung der innovativen Genio®-Therapie im Nahen Osten bekannt (EQS Group) |
Analysen zu Nyxoah S.A. Registered Shsmehr Analysen
Aktien in diesem Artikel
Nyxoah S.A. Registered Shs | 5,49 | -5,83% |
|